Last updated: 3 months ago
OKYO Pharma Unveils Milestone: OK-101 Named 'urcosimod' in SEC Form 6-K Filing
Discover OKYO Pharma's latest SEC Form 6-K report detailing the USAN assignment of lead asset OK-101 as 'urcosimod', a key development in their drug pipeline.